OCS Oculis Holding AG
Oculis Holding AG (OCS) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.54 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on November 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Oculis Holding AG
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.